Open, non-randomized phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine, to evaluate their efficacy, safety and biological pharmacodynamic effects in patients with resectable stage IB-IIIA non small cell lung cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2011
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 11 Jul 2011 New trial record